Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CYP2C9 gene segment containing 1009C>A mutation, protein segment coded by same and application thereof

A technology of fragments and nucleic acid fragments, applied in the field of biology, can solve problems such as differences in drug efficacy, insufficiency, drug toxicity and side effects, etc.

Active Publication Date: 2013-07-10
卫生部北京医院
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] According to current clinical research, this polymorphism of CYP2C9 gene is the main reason for the great difference in CYP2C9 enzyme activity among individuals, so it can cause great differences in drug efficacy among individuals carrying different CYP2C9 genotypes, Even severe drug side effects or inadequate treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CYP2C9 gene segment containing 1009C>A mutation, protein segment coded by same and application thereof
  • CYP2C9 gene segment containing 1009C>A mutation, protein segment coded by same and application thereof
  • CYP2C9 gene segment containing 1009C>A mutation, protein segment coded by same and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069]Example 1: Identification of new mutation sites in human CYP2C9 gene

[0070] In this example, the blood samples of patients with clinically low warfarin dosage were collected, the genomic DNA in the blood was extracted, and sequencing primers were designed to amplify and sequence the 9 exons of the CYP2C9 gene to analyze whether the CYP2C9 gene There are mutation sites.

[0071] 1) DNA extraction:

[0072] Take a 5ml venous EDTA anticoagulated blood sample from the subject; then extract the genomic DNA of the blood sample to be tested according to the common salting-out method and / or using a special DNA extraction kit (purchased from Omega, USA).

[0073] 2) PCR amplification:

[0074] Amplification primers were designed to amplify the 9 exon sequences of the CYP2C9 gene in the obtained genomic DNA sample. The sequences of the amplification primer pairs are shown in Table 1.

[0075] Use 50μl PCR reaction system, including: 1×PCR buffer, 1.5mM MgCl 2 , 100-150ng of...

Embodiment 2

[0090] Embodiment 2: the expression of target gene

[0091] Using the plasmid vector with the open reading frame of wild-type CYP2C9*1 (gifted by Professor Zhou Shufeng from the University of South Florida, USA) as a template, CYP2C9*2, CYP2C9*3 and the P337T mutant of the present invention were respectively obtained by site-directed mutagenesis open reading frame. The technique of site-directed mutagenesis is well known in the art, and those skilled in the art can undoubtedly know how to complete this step based on the determined template and target.

[0092] Then the ORFs of the CYP2C9*1 gene and the three mutant genes for site-directed mutagenesis were cloned into the vector pFastBac-dual connected with cytochrome P450 oxidoreductase (OR), so that the CYP2C9 gene and OR were placed in PH and p10 respectively. After that, construct a dual expression vector that simultaneously expresses OR and CYP2C9 (or its mutants). The structure of pFastBac-dual vector and the insertion ...

Embodiment 3

[0097] Example 3: In vitro analysis of the metabolic properties of diclofenac using the obtained insect microsomes:

[0098] 1) Chromatographic conditions: the chromatographic column is ZORBAX SB-C18 column (2.1*150mm, 5-Micron, Agilent, USA); the mobile phase is 0.1% TFA:water:acetonitrile=20:35:45; the column temperature is 40°C; The detection wavelength is: 280nm.

[0099] 2) Incubation conditions:

[0100] The total reaction volume is 200 μL, including: 100 mM Tris-HCl (pH7.4), 1×NADPH coenzyme generation system (Promega, USA), 2 pmol cytochrome b5 and diclofenac (purchased from Sigma, USA, the final reaction concentration is 1-100 μM ). After pre-incubation at 37°C for 5 min, 2-5 pmol of recombinant microsomes constructed in Example 2 (expressing *1, *2, *3 types of CYP2C9 and P337T of the present invention respectively) were added to start the reaction. After incubation at 37°C for 20 min, 100 μL of 0.1 M HCl and 10 μL of 20 ng / μL internal standard carbamazepine (purc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biology, relates to single-base mutation, and in particular relates to a CYP2C9 gene which is corresponding to the mutation site mutated from wild type C into A on the 1009th bit of SEQ ID NO.2, a nucleic acid segment containing the mutation site, a protein segment coded by the nucleic acid segment and application thereof. The invention also provides allele specific oligonucleotide, a kit and a detection method for detecting the mutation site.

Description

technical field [0001] The invention belongs to the field of biology and relates to single base mutation. More specifically, the present invention relates to the mutation site of CYP2C9 gene relative to the 1001st position of SEQ ID NO.1 or the 1009th position of SEQ ID NO.2, the nucleic acid fragment comprising the mutation site and the corresponding encoded protein fragment thereof . The invention also relates to a reagent and a detection method for identifying the mutation site, and the application of the identification site in guiding medication. Background technique [0002] CYP2C9 is the most important member of the CYP2C subfamily of the cytochrome P450 enzyme family, accounting for about 20% of the total CYP enzymes in human liver microsomes. About 10-16% of clinically used drugs are oxidatively metabolized by CYP2C9, mainly including tolbutamide, S-warfarin, phenytoin, glipizide, glibenclamide, toratimide, losartan, urethane Medications such as besartan and many ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/53C12N15/11C12Q1/68C12N9/02
Inventor 蔡剑平戴大鹏胡国新李传保王双虎耿培武
Owner 卫生部北京医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com